Radius Health Inc (NASDAQ:RDUS) major shareholder Growth N. V. Biotech purchased 38,259 shares of the stock in a transaction that occurred on Friday, January 22nd. The shares were purchased at an average cost of $31.67 per share, for a total transaction of $1,211,662.53. Following the completion of the acquisition, the insider now directly owns 4,360,399 shares of the company’s stock, valued at approximately $138,093,836.33. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Several institutional investors have made changes to their positions in RDUS. CenturyLink Investment Management Co acquired a new position in shares of Radius Health during the fourth quarter worth approximately $252,000. Quantitative Systematic Strategies acquired a new position in shares of Radius Health during the fourth quarter worth approximately $302,000. Meeder Asset Management acquired a new position in shares of Radius Health during the fourth quarter worth approximately $515,000. Russell Frank Co acquired a new position in shares of Radius Health during the fourth quarter worth approximately $538,000. Finally, DekaBank Deutsche Girozentrale boosted its position in shares of Radius Health by 0.9% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 21,750 shares of the biopharmaceutical company’s stock worth $1,358,000 after buying an additional 200 shares during the last quarter.

Radius Health Inc (NASDAQ:RDUS) opened at 31.14 on Thursday. Radius Health Inc has a 1-year low of $28.76 and a 1-year high of $84.64. The stock’s market capitalization is $1.34 billion. The stock has a 50 day moving average of $50.86 and a 200 day moving average of $63.30.

Radius Health (NASDAQ:RDUS) last announced its earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by $0.10. During the same quarter last year, the business earned ($0.59) EPS. On average, analysts expect that Radius Health Inc will post ($2.41) earnings per share for the current year.

RDUS has been the topic of a number of recent analyst reports. Canaccord Genuity reissued a “buy” rating and set a $85.00 price target on shares of Radius Health in a report on Monday, October 12th. JPMorgan Chase & Co. initiated coverage on shares of Radius Health in a report on Friday, October 2nd. They set an “overweight” rating and a $88.00 price target on the stock. Vetr raised shares of Radius Health from a “buy” rating to a “strong-buy” rating and set a $81.68 price target on the stock in a report on Wednesday, October 7th. Cowen and Company reissued an “outperform” rating on shares of Radius Health in a report on Sunday, October 18th. Finally, Cantor Fitzgerald reissued a “buy” rating on shares of Radius Health in a report on Friday, December 11th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $77.07.

Radius Health, Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, as well as other serious endocrine-mediated diseases. The Company’s lead product candidate is abaloparatide (NASDAQ:RDUS), a bone anabolic for use in the reduction of fractures in postmenopausal osteoporosis delivered through subcutaneous injection, which it refers to as abaloparatide-SC and is in Phase III development. The Company is leveraging its investment in Abaloparatide-SC to develop a line extension that is designed to improve patient convenience by enabling administration of abaloparatide through an investigational short-wear-time patch, which the Company refers to as abaloparatide-TD. The Company’s clinical product portfolio also includes the investigational drug RAD1901, a selective estrogen receptor down regulator/degrader (SERD) and RAD140, a nonsteroidal selective androgen receptor modulator (SARM), for the treatment of breast cancer.

12 Month Chart for NASDAQ:RDUS

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Radius Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.